March 22, 2019
A recent study found that patients with non-infectious inflammatory eye disease experience a significant clinical and economic burden.
Thomas Albini, MD, Bascom Palmer Eye Institute, University of Miami, and colleagues sought to assess the economic burden of non-infectious inﬂammatory eye disease in a commercially-insured population in the United States. The research team selected adult patients with a non-infectious inflammatory eye disease from a de-identified, privately insured claims database. This patient cohort was matched 1:1 to a control group cohort.
“Ophthalmologic complications, direct healthcare resource use and costs, and indirect work loss (from the payer perspective) were calculated for a 12-month period and compared across the 2 cohorts,” Dr Albini and colleagues explained.
The research team identified 14,876 matched pairs. According to the findings, patients with non-infectious inflammatory eye disease were more likely to experience ocular complications, such as glaucoma and cataracts, compared with the control cohort. Further, the eye disease cohort had much higher health care resource utilization and costs compared with matched controls (relative difference 40%). Finally, the researchers found that patients with non-infectious inflammatory eye disease missed approximately 12.2 days of work, which was 46% more than patients without the disease.
“[Non-infectious inflammatory eye disease] imposes a significant clinical and economic burden, suggesting an unmet need for expanded access to alternative treatment options,” Dr Albini and colleagues concluded.
Albini TA, Rice JB, White AG, et al. Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States [published online July 31, 2018]. Ocular Immunology and Inflammation. DOI: https://doi.org/10.1080/09273948.2018.1560476